DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial

Recruiting now · Not applicable

Conditions studied: Acute Coronary Syndrome

In brief

To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.

Key facts

Study ID

NCT05305482

Run by

Yonsei University

People needed

3520

Starts

2022-08-10

Expected to finish

2030-02-14

Last updated by the study team

2025-05-21

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥19 years
• All subjects who are acceptable candidates for treatment with a drug-coated stent or drug-eluting stent because of acute coronary syndrome
• Provision of informed consent

You may not qualify if…

• Current or potential pregnancy
• Need of oral anticoagulation therapy
• Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator

Where it is running

• Yonsei Cardiovascular Hospital, Yonsei University College of Medicine — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.